Optimization of a heterologous mevalonate pathway through the use of variant HMG-CoA reductases

Magali Suzanne; David E. Garcia; Alyssa M. Redding‐Johanson; Gregory D. Friedland; Rossana Chan; Tanveer S. Batth; John Haliburton; Dylan Chivian; Jay D Keasling; Christopher J. Petzold; Taek Soon Lee; Swapnil R. Chhabra

doi:10.1016/j.ymben.2011.07.001

Related publications

Article2006

Balancing a heterologous mevalonate pathway for improved isoprenoid production in Escherichia coli

Douglas J. Pitera, Christopher J. Paddon, Jack D. Newman, Jay D Keasling

Article2016

Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase

Peter Würtz, Qin Wang, Pasi Soininen, Antti J. Kangas, Ghazaleh Fatemifar, Tuulia Tynkkynen, Mika Tiainen, Markus Perola, Therese Tillin, Alun D. Hughes, Pekka Mäntyselkä, Mika Kähönen, Terho Lehtimäki, Naveed Sattar, Aroon D. Hingorani, Juan-Pablo Casas, Veikko Salomaa, Mika Kivimäki, Paul M Ridker, George Davey Smith, Mauno Vanhala, Debbie A. Lawlor, Olli T. Raitakari, Nish Chaturvedi, Johannes Kettunen, Mika Ala‐Korpela

Article2004

Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives

Dario Cattaneo, Sara Baldelli, Simona Merlini, Stefania Zenoni, Norberto Perico, Giuseppe Remuzzi

Article2014

A kinetic‐based approach to understanding heterologous mevalonate pathway function in <i>E. coli</i>

Lane J. Weaver, Mirta Mittelstedt Leal de Sousa, George Wang, Edward E. K. Baidoo, Christopher J. Petzold, Jay D Keasling

Article2006

Coenzyme Q10 production in recombinant Escherichia coli strains engineered with a heterologous decaprenyl diphosphate synthase gene and foreign mevalonate pathway

Hossein Shahbani Zahiri, Sang Hwal Yoon, Jay D Keasling, Si Hyoung Lee, Seon Won Kim, Sung Chul Yoon, Yong Chul Shin